RESUMEN
Neuroblastoma is perhaps the most heterogeneous childhood cancer in terms of clinical behavior. Stage of disease, age at diagnosis, levels of urinary catecholamine excretion, N-myc amplification, and DNA ploidy have been found to be significant prognostic factors. The aims of this combined retrospective-prospective study are to verify the prognostic significance of DNA ploidy and to show its correlation with other prognostic signs. Thirty six fresh and thirty three paraffin embedded samples from patients with histologically confirmed neuroblastoma (41 prior to receiving any chemotherapy) were available for flow cytometry DNA analysis. Our results showed that the maturation induced during chemotherapy could give rise to aneuploidy therefore we analyzed the associations between the DNA ploidy and other prognostic markers only in patients examined before chemotherapy. There were no significant correlations between DNA ploidy and urinary catecholamine metabolites levels or tumor localization. DNA aneuploidy was significantly more frequent in patients with lower clinical stage, lower age at diagnosis, and without N-myc gene amplification. Patients with DNA aneuploid neuroblastomas died less frequently than patients with DNA diploid tumors. There were no significant associations among the S-phase or proliferation fraction and other prognostic factors.
Asunto(s)
ADN de Neoplasias/genética , Neuroblastoma/genética , Ploidias , Catecolaminas/orina , Preescolar , Femenino , Ácido Homovanílico/orina , Humanos , Lactante , Masculino , Neuroblastoma/orina , Pronóstico , Estudios Prospectivos , Estudios Retrospectivos , Ácido Vanilmandélico/orinaRESUMEN
Conditions for the effective fluorescence labelling of microsporidian spores by optical brighteners, based on the presence of chitin in the spore wall, are described. Spores of Vairimorpha ephestiae, V. necatrix, V. plodiae, Nosema bombycis, N. apis, N. algerae, Encephalitozoon cuniculi and Enterocytozoon bieneusi were examined. The degree of binding of Calcofluor White M2R (CFW) to untreated spores depends on the conditions and time of storage and the degree of bacterial contamination of the spore sample. Unpurified spores, stored in water are unreliable as control material for the estimation of CFW labelling. However, spores subjected to alkaline treatment by NaOH before CFW application are visualized with ease under all experimental conditions by their bright, not quenching fluorescence in shortwave light (approximately 350 nm) in CFW dilutions of 10(-4) or even lower. Similar improvement in labelling is achieved by exposing spores to CFW dissolved in 0.5-1N NaOH. As well as Calcofluor White M2R other optical brighteners (e.g. Uvitex 2B, Ciba-Geigy or Rylux BA, Ostacolor) can be used for labelling of spores.
Asunto(s)
Infecciones Oportunistas Relacionadas con el SIDA/parasitología , Microsporida/citología , Microsporidiosis/diagnóstico , Coloración y Etiquetado/métodos , Animales , Humanos , Microscopía Fluorescente , Esporas/citologíaRESUMEN
We studied monoclonality of tumour cells by polymerase chain reaction (PCR) in paediatric lymphomas. In B-lymphomas we detected monoclonal rearrangement of the immunoglobulin of the T-cell receptor delta and gamma chain (TCR, TCR-delta, TCR-gamma) by an analogous way. We examined a group of 37 paediatric patients with lymphomas (26 with B-lymphomas and 11 with T-lymphomas). Monoclonal gene rearrangement was found in 34 cases, i.e. the method used in this study proved to be successful in 92% of cases. We confirmed our results by correlation with histologic and immunohistologic diagnoses. The method may be used as a complementary diagnostic tool in differential diagnosis of lymphoma versus non-neoplastic proliferation of lymphatic tissue, in distinction between B- and T-lymphomas, and to separate lymphomas and other malignancies. Beside the pure diagnostic usage we perceive the main importance of the method in monitoring minimal residual disease (MRD), because amplified products of PCR may be sequenced and used for preparing tumour specific primers and probes.
Asunto(s)
Reordenamiento Génico de Linfocito T , Linfoma de Células B/inmunología , Linfoma de Células T/inmunología , Receptores de Antígenos de Linfocitos T/análisis , Niño , Diagnóstico Diferencial , Humanos , Linfoma de Células B/diagnóstico , Linfoma de Células B/genética , Linfoma de Células T/diagnóstico , Linfoma de Células T/genética , Reacción en Cadena de la PolimerasaRESUMEN
Tumors of the sympathetic nervous system (NT), namely neuroblastoma (NB) and ganglioneuroblastoma (GNB), have a variable clinical course. Prognostic factors include clinical stage, age of the patient, histological grade, and changes at the genomic level, of which amplification of N-myc oncogene is a well recognized phenomenon. The aim of this study was to establish the status of the N-myc oncogene in NT and to compare the results with histopathological grading, with risk groups according to criteria outlined by Joshi et al., and with the clinical stage. To detect the amplification of N-myc oncogene we used differential polymerase chain reaction (D-PCR). Amplified N-myc oncogene was found in 10 out of 31 investigated children with NB (32%). The result of D-PCR could not be interpreted reliably in two patients. Of seven children with GNB the N-myc amplification was found in one case. None of seven children with ganglioneuroma was found to have amplified N-myc oncogene. The tumors with N-myc amplification were histologically poorly differentiated of undifferentiated with a high mitotic activity-8 children were classified as a high risk category; in two we had not enough surgical material to evaluate the histological prognostic factors. The correlation of N-myc status with clinical stage revealed N-myc amplification in two of 9 children classified as clinical stage III, and in eight of 11 children classified as clinical stage IV. The N-myc amplification was not found in any child diagnosed at stage I, II and IV. Five of 10 children with NB and N-myc amplification died of the disease progression. Four children died in the group of 19 children without N-myc amplification. The median of follow-up was 18 months. The patient with GNB and N-myc amplification also died of the disease progression. Although the follow-up period of the investigated group of patients was short, the results showed that the amplification of N-myc oncogene was associated with tumors of patients diagnosed at a late clinical stage (III and IV), and with tumors whose morphology and age were assessed collectively under the term "high risk group".